NASDAQ:AKUS

Akouos - AKUS Stock Forecast, Price & News

$3.12

+0.29 (+10.25%)

(As of 08/12/2022 09:14 PM ET)

Add

Compare

Today's Range: $2.87
▼
$3.24
50-Day Range: $2.60
▼
$5.20
52-Week Range: $2.32
▼
$13.69

Volume: 100,500 shs
Average Volume: 229,597 shs
Market Capitalization: $108.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Akouos MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 476.9% Upside
$18.00 Price Target
Short Interest: Bearish
12.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.87
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.96) to ($2.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

522nd out of 1,135 stocks

Pharmaceutical Preparations Industry

262nd out of 557 stocks

3.5

Analyst's Opinion

Consensus Rating
Akouos has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, Akouos has a forecasted upside of 476.9% from its current price of $3.12.
Amount of Analyst Coverage
Akouos has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.11% of the float of Akouos has been sold short.
Short Interest Ratio / Days to Cover
Akouos has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Akouos has recently decreased by 2.95%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Akouos does not currently pay a dividend.
Dividend Growth
Akouos does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKUS.

3.3

News and Social Media Coverage

News Sentiment
Akouos has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Akouos this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for AKUS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Akouos to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akouos insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Akouos is held by insiders.
Percentage Held by Institutions
98.06% of the stock of Akouos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Akouos are expected to grow in the coming year, from ($2.96) to ($2.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akouos is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akouos is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akouos has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akouos (NASDAQ:AKUS) Stock

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Analyst Ratings Changes

Separately, Piper Sandler cut their price objective on shares of Akouos from $40.00 to $18.00 and set an "overweight" rating on the stock in a report on Tuesday, May 17th.

Akouos Price Performance

AKUS Stock traded up $0.29 on Friday, reaching $3.12. 100,506 shares of the company traded hands, compared to its average volume of 100,721. The firm has a fifty day simple moving average of $3.65 and a 200-day simple moving average of $4.05. The company has a market cap of $108.05 million, a P/E ratio of -1.10 and a beta of -0.01. Akouos has a one year low of $2.32 and a one year high of $13.69.

Akouos (NASDAQ:AKUS - Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.05). On average, sell-side analysts forecast that Akouos will post -2.96 EPS for the current year.

Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Stock News Headlines

July 7, 2022 | nasdaq.com

Can You Pull Off Early Retirement, Despite the Recent Stock Market Downturn? - Nasdaq

July 7, 2022 | rttnews.com

Pre-market Movers: EVTV, USEA, AKUS, GME, ANVS… - RTTNews

August 15, 2022 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

June 8, 2022 | finance.yahoo.com

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors - Yahoo Finance

June 8, 2022 | finance.yahoo.com

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases - Yahoo Finance

June 7, 2022 | streetinsider.com

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors - StreetInsider.com

June 6, 2022 | businesswire.com

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors - Business Wire

May 30, 2022 | finance.yahoo.com

We're Keeping An Eye On Akouos' (NASDAQ:AKUS) Cash Burn Rate

August 15, 2022 | Investing Daily (Ad)

Potential 500% Return From A Unique $1 Asset?

Millions are rushing towards life at “Ground Zero”. A frightening new financial reality that has the potential to erase the wealth of millions. It’s largely avoidable if you know what to look for. It all hinges on a single $1 asset that skyrockets during strange times like these. Discover it now

May 19, 2022 | globenewswire.com

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting - GlobeNewswire

May 13, 2022 | benzinga.com

Akouos: Q1 Earnings Insights - Benzinga - Benzinga

May 4, 2022 | benzinga.com

Akouos to Present at Bank of America 2022 Healthcare Conference - Benzinga - Benzinga

May 4, 2022 | finance.yahoo.com

Akouos to Present at Bank of America 2022 Healthcare Conference

May 3, 2022 | globenewswire.com

Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting - GlobeNewswire

May 3, 2022 | finance.yahoo.com

Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting

March 30, 2022 | nasdaq.com

IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4 - Nasdaq

March 29, 2022 | globenewswire.com

Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - GlobeNewswire

March 29, 2022 | finance.yahoo.com

Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

March 24, 2022 | finance.yahoo.com

Akouos to Participate in Upcoming March Virtual Investor Conferences

March 21, 2022 | uk.finance.yahoo.com

Osler Diagnostics Appoints Chris Smith as Chairman of the Board and David Berry as a Non-Executive Director - Yahoo Finance UK

March 11, 2022 | benzinga.com

Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer - Benzinga - Benzinga

March 10, 2022 | streetinsider.com

Akouos (AKUS) Appoints Aaron Tward as Chief Scientific Officer - StreetInsider.com

March 10, 2022 | globenewswire.com

Akouos Appoints Aaron Tward, MD, Ph.D., as Chief Scientific Officer - GlobeNewswire

March 10, 2022 | finance.yahoo.com

Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

March 1, 2022 | finance.yahoo.com

Akouos to Present at Cowen 42nd Annual Heath Care Conference

February 9, 2022 | streetinsider.com

Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngolog - StreetInsider.com

February 8, 2022 | finance.yahoo.com

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Company Calendar

Last Earnings: 11/12/2021
Today: 8/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKUS
CUSIP: N/A
CIK: 1722271
Web: www.akouos.com
Phone: 857-410-1818
Fax: N/A
Employees: 103
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +476.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-86,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.01%
Return on Assets: -33.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.39
Quick Ratio: 11.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.77 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 34,626,000
Free Float: 32,964,000
Market Cap: $108.03 million
Optionable: Not Optionable
Beta: -0.01

Key Executives

Dr. Emmanuel Simons M.B.A. (Age 39)
Ph.D., Co- Founder, Pres, CEO & Director
Comp: $790.72k
Dr. Michael John McKenna M.D. (Age 65)
Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
Comp: $539.35k
Ms. Jennifer Anne Wellman M.S. (Age 44)
Chief Operating Officer
Comp: $568.67k
Dr. Luk H. Vandenberghe M.D.
Ph.D., Founder & Member of Scientific Advisory Board
Mr. William F. Sewell Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Richard Smith M.D.
Founder & Member of Scientific Advisory Board
Ms. Sachiyo Minegishi (Age 44)
CFO, Treasurer, Assistant Sec. & Principal Accounting Officer
Ms. Stacy Price
Chief Technical Officer
Dr. Aaron Tward M.D.
Ph.D., Chief Scientific Officer
Dr. Karoline K. Shair
Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKUS Stock - Frequently Asked Questions

Should I buy or sell Akouos stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AKUS shares.
View AKUS analyst ratings or view top-rated stocks.
What is Akouos' stock price forecast for 2022?: 1 analysts have issued 1 year target prices for Akouos' shares. Their AKUS share price forecasts range from $18.00 to $18.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price.
View analysts price targets for AKUS or view top-rated stocks among Wall Street analysts.
How have AKUS shares performed in 2022?: Akouos' stock was trading at $8.50 at the beginning of 2022. Since then, AKUS stock has decreased by 63.3% and is now trading at $3.12.
View the best growth stocks for 2022 here.
How were Akouos' earnings last quarter?: Akouos, Inc. (NASDAQ:AKUS) issued its earnings results on Friday, November, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.04.
What other stocks do shareholders of Akouos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Home Depot (HD), Pfizer (PFE) and Procter & Gamble (PG).
When did Akouos IPO?: (AKUS) raised $124 million in an IPO on Friday, June 26th 2020. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

What is Akouos' stock symbol?: Akouos trades on the NASDAQ under the ticker symbol "AKUS."
Who are Akouos' major shareholders?: Akouos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (0.59%), Capital Wealth Alliance LLC (0.29%), Renaissance Technologies LLC (0.26%), Northern Trust Corp (0.12%), Gladius Capital Management LP (0.02%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Akouos?: Shares of AKUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akouos' stock price today?: One share of AKUS stock can currently be purchased for approximately $3.12.
How much money does Akouos make?: Akouos (NASDAQ:AKUS) has a market capitalization of $108.05 million. The company earns $-86,670,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.
How many employees does Akouos have?: The company employs 103 workers across the globe.
How can I contact Akouos?: Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The official website for the company is www.akouos.com. The company can be reached via phone at 857-410-1818 or via email at turiano@sternir.com.

This page (NASDAQ:AKUS) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Akouos - AKUS Stock Forecast, Price & News

Akouos MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Akouos (NASDAQ:AKUS) Stock

Analyst Ratings Changes

Akouos Price Performance

AKUS Stock News Headlines

AKUS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AKUS Stock - Frequently Asked Questions

Should I buy or sell Akouos stock right now?

What is Akouos' stock price forecast for 2022?

How have AKUS shares performed in 2022?

How were Akouos' earnings last quarter?

What other stocks do shareholders of Akouos own?

When did Akouos IPO?

What is Akouos' stock symbol?

Who are Akouos' major shareholders?

How do I buy shares of Akouos?

What is Akouos' stock price today?

How much money does Akouos make?

How many employees does Akouos have?

How can I contact Akouos?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™